ArticleBlood advances2022

RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort.

Emilia Scalzulli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.